BR112021024491A8 - Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição - Google Patents

Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição

Info

Publication number
BR112021024491A8
BR112021024491A8 BR112021024491A BR112021024491A BR112021024491A8 BR 112021024491 A8 BR112021024491 A8 BR 112021024491A8 BR 112021024491 A BR112021024491 A BR 112021024491A BR 112021024491 A BR112021024491 A BR 112021024491A BR 112021024491 A8 BR112021024491 A8 BR 112021024491A8
Authority
BR
Brazil
Prior art keywords
treating
infection
disease
improving
preventing
Prior art date
Application number
BR112021024491A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112021024491A2 (pt
Inventor
He Jian
M Kaufhold Robin
M Skinner Julie
Xie Jinfu
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Publication of BR112021024491A2 publication Critical patent/BR112021024491A2/pt
Publication of BR112021024491A8 publication Critical patent/BR112021024491A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112021024491A 2019-06-05 2020-06-01 Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição BR112021024491A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962857534P 2019-06-05 2019-06-05
PCT/US2020/035511 WO2020247301A1 (en) 2019-06-05 2020-06-01 Methods of treating patients with an immunogenic composition that protects against s. pneumoniae serotype 29

Publications (2)

Publication Number Publication Date
BR112021024491A2 BR112021024491A2 (pt) 2022-02-15
BR112021024491A8 true BR112021024491A8 (pt) 2023-04-11

Family

ID=73653320

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024491A BR112021024491A8 (pt) 2019-06-05 2020-06-01 Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição

Country Status (10)

Country Link
US (1) US20220218812A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980050A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022535064A (cg-RX-API-DMAC7.html)
KR (1) KR20220016964A (cg-RX-API-DMAC7.html)
CN (1) CN114025784A (cg-RX-API-DMAC7.html)
AU (1) AU2020289048A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021024491A8 (cg-RX-API-DMAC7.html)
CA (1) CA3142697A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021014948A (cg-RX-API-DMAC7.html)
WO (1) WO2020247301A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
JP7680185B2 (ja) 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖-タンパク質コンジュゲートの免疫原性の増強
US11395849B2 (en) 2017-09-07 2022-07-26 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065387B (zh) 2017-09-07 2023-08-25 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
EP3720483B1 (en) 2017-12-06 2025-11-19 Merck Sharp & Dohme LLC Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2019212846A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates
JP7397000B2 (ja) 2018-04-30 2023-12-12 メルク・シャープ・アンド・ドーム・エルエルシー 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法
WO2019212842A1 (en) 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311976A1 (en) * 2009-10-19 2011-04-20 Azienda Ospedaliero-Universitaria Meyer Method for Streptococcus Pneumoniae diagnosis and serotyping
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US11058757B2 (en) * 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
CN109789198B (zh) * 2016-09-30 2024-08-16 生物E有限公司 包含多糖-蛋白缀合物的多价肺炎球菌疫苗组合物
IL267709B2 (en) * 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids

Also Published As

Publication number Publication date
EP3980050A4 (en) 2023-08-02
AU2020289048A1 (en) 2021-12-09
KR20220016964A (ko) 2022-02-10
US20220218812A1 (en) 2022-07-14
BR112021024491A2 (pt) 2022-02-15
CA3142697A1 (en) 2020-12-10
WO2020247301A1 (en) 2020-12-10
MX2021014948A (es) 2022-01-24
JP2022535064A (ja) 2022-08-04
CN114025784A (zh) 2022-02-08
EP3980050A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
BR112021024491A2 (pt) Composição imunogênica, e, método para prevenir, tratar ou melhorar uma infecção, doença ou condição
DOP2021000127A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
ECSP20032085A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
BR112013006396A2 (pt) composições imunogênicas
BR112021021637A2 (pt) Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
NZ760783A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112019006278A2 (pt) composições de vacina pneumocócica multivalente que compreendem conjugados de polissacarídeo-proteína
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
BR112019004303A2 (pt) composição de conjugados multivalentes de polissacarídeo capsular pneumocócico-proteína portadora e uso da mesma
BR112018069100A2 (pt) uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
MX2020006662A (es) Vacuna combinada intradermica contra mycoplasma y circovirus porcino.
BR112021026499A2 (pt) Formulação gastrorretentiva de liberação prolongada contra helicobacter pylori
BR112022019207A2 (pt) Composições de vacina para coronavírus e métodos de uso das mesmas
WO2019157188A3 (en) Compositions and methods for cross-protection against pneumococcal disease
BR112017028395A2 (pt) ?polissacarídeo capsular bacteriano, conjugado, e, composição farmacêutica?
MX2021015155A (es) Polisacaridos de ramnosa.
MX388528B (es) Vacuna que comprende toxoides de clostridium.
BR112018069219A2 (pt) uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
EA202191647A1 (ru) Композиции, содержащие конъюгаты полисахарида из streptococcus pneumoniae и белка, и способы их применения
RU2021138121A (ru) Способы лечения пациентов иммуногенной композицией, защищающей от серотипа 29 s. pneumoniae
AR104514A1 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]